BN  ImmunoTherapeutics, Inc. (Mountain View, CA), has initiated Phase 1/2 clinical  studies with its therapeutic vaccine candidate against prostate cancer.

  A  Phase 1/2 safety and tolerability study in 18 male patients with nonmetastatic  as well as hormone-insensitive prostate cancer has begun enrollment in the US.  Secondary objectives of the trial include examining the ability of the vaccine  to induce prostate antigen-specific immune responses, as well as clinical  anti-tumor activity. Preliminary data is expected during the second half of  2009.

  The  therapeutic vaccine, based on the company's MVA-BN(R) technology, is designed  to generate cellular and humoral immune responses to prostate specific antigen  (PSA) and prostatic acid phosphatase (PAP), which are both well-known prostate  cancer tumor targets.

News

BN ImmunoTherapeutics, Inc. (Mountain View, CA), has initiated Phase 1/2 clinical studies with its therapeutic vaccine candidate against prostate cancer.